Ariad Pharmaceuticals has announced updated Phase I/II clinical data on its investigational tyrosine kinase inhibitor brigatinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer. 17 April 2015
US biotech company RXi Pharmaceuticals Corporation has been granted Orphan Drug Designation by the US Food and Drug Administration for its second clinical candidate, Samcyprone, for the treatment of Malignant Melanoma Stage IIb to IV. 17 April 2015
US drug majors Eli Lilly and Bristol-Myers Squibb have agreed to transfer the rights to Erbitux (cetuximab) in North America from Bristol-Myers Squib to Lilly. 17 April 2015
Anglo-Swedish drug major AstraZeneca has been granted orphan drug designation by the US Food and Drug Administration for selumetinib, and has announced updated progression-free survival data for AZD9291. 17 April 2015
Danish biotech company Bavarian Nordic, which focuses on vaccines and novel cancer immunotherapies, has greatly benefited from deals with US pharma major Bristol-Myers Squibb and Johnson & Johnson. 16 April 2015
MedImmune, the global biologics arm of AstraZeneca, has entered into a collaboration to conduct immuno-oncology clinical trials with privately-held UK biotech company Immunocore. 16 April 2015
Anglo-Swedish drug major AstraZeneca has been granted orphan drug designation by the US Food and Drug Administration for tremelimumab in the treatment of malignant mesothelioma. 16 April 2015
The global treatment market for melanoma will expand more than fourfold in value from $1.34 billion in 2013 to reach an estimated $5.64 billion by 2023, representing a robust compound annual growth rate (CAGR) of 15.5%. 16 April 2015
Treatment with Arzerra (ofatumumab) from Novartis plus chlorambucil resulted in a statistically significant improvement in progression-free survival versus chlorambucil alone in a section of leukemia patients. 15 April 2015
German pharma major Bayer has announced the expansion of its global clinical development program for the investigational oncology compound copanlisib (BAY 80-6946). 14 April 2015
Ophthalmic specialist biopharma company ThromboGenics has founded Oncurious, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors. 14 April 2015
Australia’s Mesoblast has entered into an Agreement with US biotech firm Celgene whereby the latter will purchase Mesoblast stock and has a six-month right of first refusal to certain disease fields. 14 April 2015
The Scottish Medicines Consortium (SMC) today announced that German pharma major Bayer’s Stivarga (regorafenib) has been accepted for use within NHS Scotland. 13 April 2015
The Russian General Prosecutor Office and the Federal Antimonopoly Service (FAS) have initiated a new wave of massive checks of national pharmacies and pharmaceutical producers, which are suspected of being responsible for a significant increase of prices for their products, reports The Pharma letter’s local correspondent. 9 April 2015
New Zealand’s Pharmaceuticals Management Agency PHARMAC will begin funding for the prostate cancer treatment abiraterone (Zytiga) from May 1, 2015, potentially benefiting up to 1,000 men annually. 9 April 2015
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024